6533b829fe1ef96bd12899aa

RESEARCH PRODUCT

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Simona DoniņaIneta NemiroElizabete PumpurePēteris AlbertsRaimundas MeskauskasAgnija RasaDana KigitovičaTatjana ZablockaEvija OlmaneSergejs IsajevsEva Dručka

subject

Oncologymedicine.medical_specialtyRigvirmedicine.medical_treatmentlcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAdjuvant therapymelanomaMedicineRadical surgeryStage (cooking)ECHO-7 virusoncolytic viruslcsh:R5-920business.industryMelanomalcsh:RGeneral Medicinemedicine.diseaseOncolytic virusTolerability030220 oncology & carcinogenesisoncologyECHO‐7 virusbusinesslcsh:Medicine (General)AdjuvantRare diseaseuterine cervix

description

Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

10.1002/ccr3.2928https://doaj.org/article/b5343f8dc6e245e9b9688295ac08bda0